Oxytocin Intervention Mitigates Pathological and Behavioral Impairments in APP/PS1 Mice Subjected to Early Social Isolation.
Level 5 - mechanism / opinion, no new human data
Preclinical animal model study (APP/PS1 mice)
PubMed 40635450 · doi:10.1111/cns.70511
What was done
Researchers subjected early-stage APP/PS1 Alzheimer's disease (AD) mice to a 12-week social isolation (SI) protocol. They assessed anxiety-like, depression-like, and social cognitive behaviors. Using immunofluorescence, enzyme-linked immunosorbent assay (ELISA), and 16S rDNA sequencing, they evaluated prefrontal cortex pathology (Aβ plaque deposition, microglial proliferation, PSD-95 expression), endogenous oxytocin (OXT) and oxytocin receptor levels, gut microbiota alterations, and the therapeutic impact of exogenous oxytocin intervention.
What was found
The abstract reports directional changes without numeric values or effect sizes. Social isolation increased anxiety- and depression-like behaviors, worsened social cognitive deficits, lowered OXT levels, upregulated OXT receptors, elevated Aβ plaque deposition and microglial proliferation, reduced PSD-95 expression in the prefrontal cortex, and altered gut microbiota composition. Oxytocin treatment mitigated these behavioral impairments, reduced the observed neuropathological markers, and restored gut microbiota homeostasis.
Why it matters
It highlights oxytocin as a potential neuromodulatory target to counteract the neuropsychiatric and neuropathological exacerbation triggered by social isolation in early Alzheimer's disease models, suggesting a gut-brain axis connection.
Limits
The study was conducted entirely in a transgenic mouse model (APP/PS1), limiting direct translation to human Alzheimer's disease. The abstract provides no exact sample sizes, dosage details, administration routes, effect sizes, or quantitative confidence intervals.
Cited by
- supports In animal models of Alzheimer's disease, oxytocin has been shown to reduce the toxicity of amyloid-beta plaques.